Cited by 276Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes Management and Education

Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin‐treated type 1 and type 2 diabetes: the global HAT study

Open access
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P. +9 more·2016·Diabetes Obesity and Metabolism

Abstract

AIMS: To determine the global extent of hypoglycaemia experienced by patients with diabetes using insulin, as there is a lack of data on the prevalence of hypoglycaemia in developed and developing countries. METHODS: This non-interventional, multicentre, 6-month retrospective and 4-week prospective study using self-assessment questionnaire and patient diaries included 27 585 patients, aged ≥18 years, with type 1 diabetes (T1D; n = 8022) or type 2 diabetes (T2D; n = 19 563) treated with insulin for >12 months, at 2004 sites in 24 countries worldwide. The primary endpoint was the proportion of patients experiencing at least one hypoglycaemic event during the observational period. RESULTS: During the prospective period, 83.0% of patients with T1D and 46.5% of patients with T2D reported hypoglycaemia. Rates of any, nocturnal and severe hypoglycaemia were 73.3 [95% confidence interval (CI) 72.6-74.0], 11.3 (95% CI 11.0-11.6) and 4.9 (95% CI 4.7-5.1) events/patient-year for T1D and 19.3 (95% CI 19.1-19.6), 3.7 (95% CI 3.6-3.8) and 2.5 events/patient-year (95% CI 2.4-2.5) for T2D, respectively. The highest rates of any hypoglycaemia were observed in Latin America for T1D and Russia for T2D. Glycated haemoglobin level was not a significant predictor of hypoglycaemia. CONCLUSIONS: We report hypoglycaemia rates in a global population, including those in countries without previous data. Overall hypoglycaemia rates were high, with large variations between geographical regions. Further investigation into these differences may help to optimize therapy and reduce the risk of hypoglycaemia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12689

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Occurrences of severe hypoglycemia and DKA (9.0 and 0.6 events per 100 person-years, respectively, in the safety cohort) observed during the study period are in line with other literature with estimates ranging from 7 to 130 and 4 to 8 events per 100 person-years, respectively, in insulin-requiring diabetes populations using MDI therapy.

    “Occurrences of severe hypoglycemia and DKA (9.0 and 0.6 events per 100 person-years, respectively, in the safety cohort) observed during the study period are in line with other literature with estimates ranging from 7 to 130 and 4 to 8 events per 100 person-years, respectively, in insulin-requiring diabetes populations using MDI therapy (39-43).”

    From Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis (2025) · cites this paper as [42]

    Split into 2 atoms — 0 confirmed, 1 partially supported, 1 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters‐Weijnen, C., Forsén, T., Galstyan, G., Geelhoed‐Duijvestijn, P., Goldfracht, M., Gydesen, H., Kapur, R., Lalic, N., Ludvik, B., Moberg, E., Pedersen‐Bjergaard, U., Ramachandran, A., & on behalf of the HAT Investigator Group
Affiliations
  • University of Leicester (GB)
  • Armed Forces Hospital (SA)
  • LMC Diabetes & Endocrinology (Canada) (CA)
  • University Hospital ‘Sestre Milosrdnice’ Zagreb Croatia
  • Julius Clinical/Julius Center UMC Utrecht Zeist the Netherlands
  • University of Helsinki (FI)
  • Endocrinology Research Center (RU)
  • Medical Center Haaglanden The Hague the Netherlands
  • Technion – Israel Institute of Technology (IL)
  • Novo Nordisk (Denmark) (DK)
  • University of Belgrade (RS)
  • Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
  • Karolinska Institutet (SE)
  • Nordsjællands Hospital (DK)
  • India Diabetes Research Foundation (IN)
Corresponding author
Khunti, K.
Venue
Diabetes Obesity and Metabolism
Publisher
Wiley
Published
2016-06-20
Volume
18
Issue
9
Pages
907-915
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2388825372
Cited by
276
References
27
Citations by year
2026: 22 · 2025: 21 · 2024: 32 · 2023: 23 · 2022: 25 · 2021: 26 · 2020: 30 · 2019: 28 · 2018: 42 · 2017: 23 · 2016: 3
FWCI
32.17
Type
journal article
Language
en
Open access
Locations
  • Diabetes Obesity and Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Figshare (submittedVersion, cc-by)
  • Työväentutkimus Vuosikirja (submittedVersion, other-oa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • National Institute for Health Research
  • Novo Nordisk
  • Bristol-Myers Squibb
  • AstraZeneca
  • Sanofi
  • Boehringer Ingelheim
  • Medtronic
  • Takeda Pharmaceuticals U.S.A.
  • Medpace
  • GlaxoSmithKline
  • Pfizer
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
hypoglycemia, insulin-treated diabetes, type 1 diabetes, type 2 diabetes, nocturnal hypoglycemia, severe hypoglycemia, HbA1c
MeSH terms
Adult, Aged, Asia, Southeastern, Canada, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Europe, Europe, Eastern, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Latin America, Male, Middle Aged, Middle East, Prospective Studies, Surveys and Questionnaires, Retrospective Studies, Risk Factors, Russia, Severity of Illness Index, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review